尼莫地平在防治蛛网膜下腔出血后脑血管痉挛的Meta分析

    Nimodipine for cerebral vasospasm after subarachnoid hemorrhage: a Meta analysis

    • 摘要: 目的:系统评价尼莫地平注射液治疗蛛网膜下腔出血(subarachnoid hemorrhage,SAH)后脑血管痉挛(cerebral vasospasm,CVS)的临床疗效及安全性。方法:检索1994~2007年国内发表的尼莫地平注射液治疗SAH后CVS临床对照试验的相关文献,利用M eta分析方法,采用Review Manager 4.2软件对符合条件的文献进行荟萃分析。结果:对符合标准的16项临床研究结果进行同质性检验表明各试验具有同质性(P>0.05)。Meta分析结果表明尼莫地平注射液能够减少住院期间SAH后CVS的发生率,病死率明显低于对照组(P<0.000001);不会引起再出血发生率的增加(P=0.17)。结论:现有的临床研究证据显示尼莫地平能够有效防治SAH后CVS,降低病死率且未增加再出血的危险。

       

      Abstract: Objective:To evaluate systematically the efficacy and safety of nimodipine injection in the treatment of patients suffering from cerebral vasospasm after subarachnoid hemorrhage.Methods:By overall collecting the related literature of controlled clinical trials about nimodipine injection for the treatment of cerebral vasospasm after subarachnoid hemorrhage from 1994 to 2007,Meta analysis was conducted by means of Review with Manager 4.2 software.Results:The homogenecity test of 16 selected clinical research showed that they had homogenicity (P>0.05).The result of Meta analysis showed that the rate of cerebral vasospasm and mortality rate after subarachnoid hemorrhage was much lower in nimodipine group than the control group (P<0.000001).The rate of rehaemorrhagia had no difference between the two groups (P=0.17).Conclusions:The evidence available shows that nimodipine is effective and safe in the treatment of cerebral vasospasm after subarachnoid hemorrhage and does not raise the risk of re-hemorrhage.

       

    /

    返回文章
    返回